House Energy and Commerce Committee Republican Leader Cathy McMorris Rodgers (R-WA) released the following statement regarding the U.S. Food and Drug Administration (FDA) User Fee Agreements and key priorities in the FDA Act of 2022 that still require Senate action.
“In June, the People’s House passed the FDA Act of 2022 with overwhelming bipartisan support to reauthorize FDA’s user fee agreements, lower drug costs, spur more lifesaving cures and treatments, and secure our supply chains. These are all critical priorities to ensure America wins the future in medical innovation.
“Because the Senate was not able to also pass a bipartisan bill, the CR that passed Congress today only included a five-year reauthorization. It extended other expiring programs and authorities until December. There is more work to do by both the Majority and Minority Committee leaders in the Senate to send provisions from the House-passed bill to the president’s desk. For patients relying on faster access to cures, more innovation, and lower costs, I remain committed to working on these priorities with my colleagues before the end of this Congress.”
Original source can be found here.
